Literature DB >> 26246683

Play of Chance Versus Concerns Regarding Dipeptidyl Peptidase-4 Inhibitors: Heart Failure and Diabetes.

Vani P Sanon, Saurabh Sanon, Son V Pham, Robert Chilton.   

Abstract

Entities:  

Year:  2014        PMID: 26246683      PMCID: PMC4521433          DOI: 10.2337/diaclin.32.3.121

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN: 0891-8929


× No keyword cloud information.
  11 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Authors:  William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

Review 3.  Clinical practice. Systolic heart failure.

Authors:  John J V McMurray
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

Review 4.  Heart failure.

Authors:  John J V McMurray; Marc A Pfeffer
Journal:  Lancet       Date:  2005 May 28-Jun 3       Impact factor: 79.321

5.  Neuropeptide Y overflow and metabolism in skeletal muscle arterioles.

Authors:  Kirk W Evanson; Audrey J Stone; Allyson L Hammond; Heidi A Kluess
Journal:  J Physiol       Date:  2011-05-09       Impact factor: 5.182

6.  A pooled analysis of waist circumference and mortality in 650,000 adults.

Authors:  James R Cerhan; Steven C Moore; Eric J Jacobs; Cari M Kitahara; Philip S Rosenberg; Hans-Olov Adami; Jon O Ebbert; Dallas R English; Susan M Gapstur; Graham G Giles; Pamela L Horn-Ross; Yikyung Park; Alpa V Patel; Kim Robien; Elisabete Weiderpass; Walter C Willett; Alicja Wolk; Anne Zeleniuch-Jacquotte; Patricia Hartge; Leslie Bernstein; Amy Berrington de Gonzalez
Journal:  Mayo Clin Proc       Date:  2014-03       Impact factor: 7.616

7.  The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota.

Authors:  Sanjay Dandamudi; Joshua Slusser; Douglas W Mahoney; Margaret M Redfield; Richard J Rodeheffer; Horng H Chen
Journal:  J Card Fail       Date:  2014-02-24       Impact factor: 5.712

8.  Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.

Authors:  Juhaeri Juhaeri; Shujun Gao; Wanju S Dai
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-06       Impact factor: 2.890

9.  Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients.

Authors:  Liu Qiang; Li Hong; Wang Ningfu; Chen Huaihong; Wang Jing
Journal:  Int J Cardiol       Date:  2013-03-07       Impact factor: 4.164

10.  Heart failure prevalence, incidence, and mortality in the elderly with diabetes.

Authors:  Alain G Bertoni; W Gregory Hundley; Mark W Massing; Denise E Bonds; Gregory L Burke; David C Goff
Journal:  Diabetes Care       Date:  2004-03       Impact factor: 19.112

View more
  4 in total

Review 1.  DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.

Authors:  Jixin Zhong; Andrei Maiseyeu; Stephen N Davis; Sanjay Rajagopalan
Journal:  Circ Res       Date:  2015-04-10       Impact factor: 17.367

Review 2.  Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors.

Authors:  Vasiliki Bistola; Vaia Lambadiari; George Dimitriadis; Ioannis Ioannidis; Konstantinos Makrilakis; Nikolaos Tentolouris; Apostolos Tsapas; John Parissis
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

3.  DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.

Authors:  Francesco Paneni
Journal:  Cardiovasc Diagn Ther       Date:  2015-12

Review 4.  Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS.

Authors:  Samit Ghosal; Binayak Sinha
Journal:  J Diabetes Res       Date:  2015-11-15       Impact factor: 4.011

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.